International Journal of Rheumatic Diseases最新文献

{"title":"Adalimumab Versus JAK Inhibitors in Juvenile Idiopathic Arthritis","authors":"Tsai-Yi Hung, Yung-Heng Lee, Brian Shiian Chen, Chen Dong, An-Ping Huo","doi":"10.1111/1756-185x.70368","DOIUrl":"https://doi.org/10.1111/1756-185x.70368","url":null,"abstract":"<p>Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease that begins in childhood and is characterized by persistent joint inflammation. It includes a diverse and heterogeneous group of conditions categorized into seven subtypes based on clinical manifestations, genetic, and serological factors [<span>1</span>]. If left untreated, JIA can lead to a poor health-related quality of life (HRQoL), significant functional impairment, and disability. According to the American College of Rheumatology (ACR) guidelines, first-line treatment for JIA typically involves nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular glucocorticoids, and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). If the response is inadequate, biological DMARDs (bDMARDs), such as tumor necrosis factor inhibitors (TNFi), may be considered as a second-line treatment [<span>2</span>]. With ongoing advances in pharmacotherapy, Janus kinase inhibitors (JAKi) have also emerged as a treatment option.</p><p>TNFi effectively manages JIA by targeting and neutralizing TNF-α, a key cytokine driving inflammation in immune-mediated conditions. Currently, the TNFi available for treating JIA include adalimumab, etanercept, golimumab, and infliximab. A systematic review found limited evidence of differences in the efficacy and safety of TNFi across various JIA categories [<span>3</span>], although a 2017 review noted variable responses to biologics by JIA category and underrepresentation of specific categories in studies [<span>4</span>].</p><p>A randomized controlled trial (RCT) indicates that adalimumab, either alone or in combination with methotrexate, is an effective treatment for children with JIA. It significantly reduces joint inflammation and swelling [<span>5</span>]. Additional research has also evaluated the long-term safety and efficacy of adalimumab for JIA patients, finding that it is well tolerated and leads to significant clinical improvements. However, its retention rate is relatively low, mainly due to non-treatment-related factors [<span>6</span>]. Despite significant advancements in treatment over the past two decades, approximately one-quarter of patients with JIA remain resistant to these therapies [<span>7</span>]. This underscores the need to develop new medications explicitly targeting these challenging cases.</p><p>JAKi is a novel class of small-molecule medications. In contrast to the injectable options required for bDMARDs, their oral formulation may improve medication adherence. This is particularly beneficial for children, adolescents, and individuals with needle aversion. JAKi reduces inflammation and modulates immune responses by inhibiting Janus kinase activity, which blocks cytokine signaling—a key driver of various inflammatory processes. Different JAKis target distinct JAK enzymes, resulting in varied clinical applications in JIA subtypes. According to phase 3 clinical trials, tofacitinib is approved for polyart","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185x.70368","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144681171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Practice Consensus Statement 2025: Management of Hyperuricemia and Gout in Adolescents","authors":"Changgui Li,&nbsp;Jie Lu,&nbsp;Zhaohui Lyu,&nbsp;Haibing Chen,&nbsp;Benli Su,&nbsp;Bo Ban,&nbsp;Jianhua Mao,&nbsp;Ping Liu,&nbsp;Zhifeng Cheng,&nbsp;Jun Zhu,&nbsp;Naijun Wan,&nbsp;Xiaobo Chen,&nbsp;Chunxiu Gong,&nbsp;Peiyu Ye,&nbsp;Mingshu Sun,&nbsp;Wenyan Sun,&nbsp;Hui Zhang,&nbsp;Han Yin,&nbsp;Xiaoyun Jiang,&nbsp;Qing Wang,&nbsp;Yaolong Chen,&nbsp;Hsiao-Yi Lin,&nbsp;Jie Mi,&nbsp;Jiajun Zhao","doi":"10.1111/1756-185x.70378","DOIUrl":"https://doi.org/10.1111/1756-185x.70378","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In response to the increasing global prevalence of gout, there is a concerning shift towards a younger demographic, with China at the forefront of this trend. Hyperuricemia, a central factor in the pathogenesis of gout, is becoming increasingly common among adolescents, particularly males, and is associated with various health risks, including joint pain, CKD, metabolic disorders, and premature death. Despite the seriousness of this issue, there is a lack of specific guidelines addressing adolescent and hyperuricemia gout management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The working comprising 26 clinician pediatricians, rheumatologists, and endocrinologists, all experienced in the clinical presentation and management of gout and hyperuricemia, was convened to develop a consensus. A systematic literature search was conducted in PubMed, the Cochrane Library, and EMBASE published from 1 January 1960 to 31 May 2024. Two rounds of Delphi surveys for each recommendation were conducted among all group members via electronic questionnaire.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Adolescent-onset gout is characterized by a pronounced genetic predisposition and distinct environmental influences, with a significant number of cases reporting a positive family history. We issued three consensus statements with five recommendations including the criteria, the urate-lowering treatment, and flare therapy principles for hyperuricemia and gout in adolescents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This consensus statement comprehensively delves into the critical clinical challenges associated with gout and hyperuricemia in the adolescent population, emphasizing the pressing requirement for improved detection and management strategies to support a demographic that may be underserved by the healthcare system.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185x.70378","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Sacroiliitis in Familial Mediterranean Fever Mimicking Septic Arthritis—A Diagnostic Challenge","authors":"Mert Tokatlı,&nbsp;Büşra Fırlatan Yazgan,&nbsp;Buğu Bulat,&nbsp;Ahmet Gürkan Erdemir,&nbsp;Levent Kılıç","doi":"10.1111/1756-185x.70369","DOIUrl":"https://doi.org/10.1111/1756-185x.70369","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric Analysis of Juvenile Idiopathic Arthritis From 2012 to 2023","authors":"Shuolan Jing,&nbsp;Shihao Li,&nbsp;Liqun Dong","doi":"10.1111/1756-185x.70359","DOIUrl":"https://doi.org/10.1111/1756-185x.70359","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Term Effectiveness of Sulfasalazine and Tofacitinib in NSAID-Refractory Reactive Arthritis: An Observational Study","authors":"Prakashini Mruthyunjaya,&nbsp;Debashis Maikap,&nbsp;Sakir Ahmed,&nbsp;Ramnath Misra,&nbsp;Prasanta Padhan","doi":"10.1111/1756-185x.70370","DOIUrl":"https://doi.org/10.1111/1756-185x.70370","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Reactive arthritis (ReA) is a lower-limb predominant oligoarthritis that follows genitourinary or gastrointestinal infection with a 2–4 week latency. Up to 40% can progress to chronicity. There is no approved disease-modifying anti-rheumatic drug for ReA yet.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Fifty consecutive patients of ReA, defined by Braun criteria, refractory to NSAIDs were included, with 25 in each group (Sulfasalazine group, tofacitinib group). Forty-six patients completed the study. The primary endpoint was DAREA (Disease Activity Index for the Assessment of Reactive Arthritis) at week 12 between the two groups. Complete response (CR), partial response (PR) and no response (NR) were defined based on DAREA of ≤ 5, 6–10, and &gt; 10, respectively. Secondary endpoints were pain VAS, ESR, CRP, BASFI, MASES, and ASDAS-CRP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 46 patients who completed the study, 70% were males, with HLA-B27 positivity in 65%. Twenty-one received sulfasalazine and 25, tofacitinib. The median DAREA at 12 weeks [3.35 (IQR: 2.77–9.18) vs. 3.05 (IQR: 2.69, 8.45), respectively)] was comparable between the two groups (<i>p</i> = 0.545). The decline in CRP, ESR, and DAREA was quicker in the tofacitinib group (by week 4). Change from baseline to 12 weeks in DAREA and the secondary endpoints was statistically significant within both groups (<i>p</i> &lt; 0.001). 25% of patients in the tofacitinib group and 18.2% in the sulfasalazine group had NR. There were no serious adverse events in either group by week 12.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Sulfasalazine and tofacitinib showed comparable effectiveness and safety in NSAID-refractory ReA at 12 weeks, with tofacitinib exhibiting a more rapid onset of therapeutic response.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noncanonical Differentiation of Memory B Cells Drives Latent Tuberculosis Infection Reactivation Upon Tumor Necrosis Factor-Alpha Inhibitor Therapy: An Integrative Transcriptomic Study","authors":"Xinyu Yu,&nbsp;Dong Liu,&nbsp;Xiqing Luo,&nbsp;Xianghui Wen,&nbsp;Zena Chen,&nbsp;Shude Chen,&nbsp;Budian Liu,&nbsp;Jinwei Li,&nbsp;Yuxuan Zhang,&nbsp;Jieruo Gu","doi":"10.1111/1756-185X.70311","DOIUrl":"https://doi.org/10.1111/1756-185X.70311","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Tumor necrosis factor inhibitors (TNFi) are widely used for the treatment of autoimmune diseases, with latent tuberculosis infection (LTBI) reactivation being a significant unresolved issue. The pathogenic mechanisms are not fully understood. Integrated transcriptomic analysis could provide insights into monitoring tuberculosis progression after TNFi therapy and help reduce LTBI reactivation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We selected six transcriptomic datasets from studies related to TNFi treatment and tuberculosis. Pathway enrichment, pseudotime, and transcription factor analyses were performed to explore the underlying mechanisms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our analysis revealed distinct transcriptional changes in memory B cells during tuberculosis progression and TNFi therapy. In active tuberculosis (ATB), ROR1⁺ memory B cells were identified in a noncanonical differentiation trajectory, characterized by downregulation of B cell-related genes (e.g., CD22, EBF1, MS4A1), reduced translational capacity, and suppression of immune response pathways, accompanied by upregulation of oxidative phosphorylation, which highlighted metabolic alterations during tuberculosis progression. A similar subtype also emerged in TNFi-treated patients, suggesting that metabolic reprogramming of memory B cells may disrupt immune balance, thereby contributing to LTBI reactivation and ATB development following TNFi therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The study integrates bioinformatics and single-cell RNA sequencing to reveal the role of memory B cells in ATB progression and TNFi treatment, offering insights into TNFi-associated TB susceptibility and potential therapeutic targets.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General Patients","authors":"Mingshu Sun,&nbsp;Zhaohui Lyu,&nbsp;Can Wang,&nbsp;Yan Li,&nbsp;Dongbao Zhao,&nbsp;Xingwu Ran,&nbsp;Haibing Chen,&nbsp;Benli Su,&nbsp;Xiangyun Chang,&nbsp;Ping Liu,&nbsp;Dewen Yan,&nbsp;Xiuyun Jiang,&nbsp;Kang Chen,&nbsp;Jiaqing Shao,&nbsp;Xiaochun Teng,&nbsp;Yongli Yao,&nbsp;Yuming Li,&nbsp;Ying Chen,&nbsp;Jidong Cheng,&nbsp;Zhifeng Cheng,&nbsp;Zhen Liu,&nbsp;Fengjing Liu,&nbsp;Xinyu Li,&nbsp;Huiyong Yin,&nbsp;Chao Liu,&nbsp;Hsiao-Yi Lin,&nbsp;Yaolong Chen,&nbsp;Wen-Chan Tsai,&nbsp;Ronald M. L. Yip,&nbsp;Changgui Li,&nbsp;Jiajun Zhao","doi":"10.1111/1756-185x.70375","DOIUrl":"https://doi.org/10.1111/1756-185x.70375","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In 2018, the Chinese Society of Endocrinology developed the “Chinese guideline for diagnosis and treatment of hyperuricemia and gout (2019)”. Over the past 5 years, clinical and experimental research has expanded our knowledge of gout, resulting in novel diagnostic and therapeutic approaches. This update, prompted by new clinical challenges and gaps in evidence, aims to refine the 2019 guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The working group formulated clinical questions based on a nationwide questionnaire survey, and the expert panel evaluated new evidence addressing these questions from January 2019 to March 2025. The guideline development followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, adhering to internationally recognized protocols for clinical practice guideline development.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The update includes 26 recommendations addressing 10 clinical questions related to urate-lowering therapy (ULT) for asymptomatic hyperuricemia and reproductive populations, anti-inflammatory treatments, urine alkalinization, dietary advice, and gout diagnosis in patients without a record of hyperuricemia and gout flare predictions in patients with asymptomatic hyperuricemia and intermittent gout. It recommends febuxostat as a first-line ULT for asymptomatic hyperuricemia and using it with caution during pregnancy and lactation. ULT should be customized according to the pathophysiologic type of hyperuricemia. Chronic gout management includes maintaining serum urate levels between 180 and 300 μmol/L and prolonged glucocorticoid tapering in combination with colchicine. Alkalinization with citrate is preferred over sodium bicarbonate for patients with urine pH &lt; 6.0. Novel biomarkers for predicting gout flares are proposed for high-risk populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These updated guidelines incorporate expert consensus and evidence to provide refined strategies for the diagnosis, prevention, and treatment of hyperuricemia and gout.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185x.70375","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK Inhibitors: Therapeutic Prospects and Clinical Challenges in Sjögren's Syndrome","authors":"Xiaoyu Tang,&nbsp;Po-Cheng Shih,&nbsp;Jingjin Hu,&nbsp;Dan Ma,&nbsp;Liyun Zhang","doi":"10.1111/1756-185x.70377","DOIUrl":"https://doi.org/10.1111/1756-185x.70377","url":null,"abstract":"&lt;p&gt;Sjögren's syndrome (SS) is a systemic autoimmune disorder primarily characterized by lymphocytic infiltration of exocrine glands, resulting in hallmark clinical manifestations such as keratoconjunctivitis sicca and xerostomia. Beyond glandular involvement, SS frequently presents with various extraglandular complications, including nephropathy, neuropathy, and interstitial lung disease (ILD). It is classified into primary and secondary subtypes. Secondary SS typically occurs secondary to other connective tissue diseases, such as rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). This article focuses primarily on the pSS, with only partial discussion of the sSS. The pathogenesis of SS is multifactorial, involving an intricate interplay among genetic susceptibility, environmental exposures, and immune dysregulation. Current therapeutic strategies for SS predominantly emphasize symptomatic relief and immunomodulation. However, rigorous, evidence-based guidelines and well-validated criteria for assessing therapeutic efficacy remain inadequately established [&lt;span&gt;1&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Emerging insights into the pathogenic mechanisms underlying SS have opened novel therapeutic directions. Cytokines are central to the pathogenesis of SS, mediating immune activation and lymphocyte proliferation. Upon binding to their corresponding receptors, cytokines such as type I interferon (IFN-I), interleukins (IL), and transforming growth factor (TGF) can activate associated Janus kinases (JAK) [&lt;span&gt;2&lt;/span&gt;]. Activated Janus kinases subsequently phosphorylate specific tyrosine residues on cytokine receptors, facilitating the recruitment and phosphorylation of signal transducer and activator of transcription (STAT) proteins. Phosphorylated STAT proteins form homodimers or heterodimers through their Src homology 2 (SH2) domains, translocate into the nucleus, and bind to specific DNA sequences to modulate gene transcription and subsequent expression of target genes [&lt;span&gt;3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;JAK inhibitors represent a promising therapeutic class, capable of concurrently modulating multiple cytokine pathways via inhibition of the common JAK–STAT signaling cascade. Thus, they hold potential for treating several systemic autoimmune diseases, including SS, systemic lupus erythematosus (SLE), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc).&lt;/p&gt;&lt;p&gt;The JAK kinase family comprises four members: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). JAK inhibitors primarily target the catalytic kinase (JH1) and regulatory pseudokinase (JH2) domains. Both first-generation (tofacitinib, baricitinib, and ruxolitinib) and next-generation inhibitors bind to the ATP-binding pocket of JH1, competitively preventing ATP binding and blocking the JAK–STAT pathway [&lt;span&gt;3&lt;/span&gt;]. There are seven known members of the signal transducer and activator of transcription (STAT) family. Among them, phosphorylated STAT1 (pSTAT1) and phosphorylated STAT3 (pSTAT3) are fou","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185x.70377","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assisted Reproductive Technologies Outcomes in Women With Rheumatic Diseases: A Retrospective Cohort Study","authors":"Elham Manouchehri,&nbsp;Fatemeh Jalalmarvi,&nbsp;Vahid Ghavami,&nbsp;Zahra Mirfeizi,&nbsp;Nayereh Khadem,&nbsp;Maryam Sahebari","doi":"10.1111/1756-185x.70374","DOIUrl":"https://doi.org/10.1111/1756-185x.70374","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The multisystem nature of rheumatic diseases (RDs) as well as their treatments can affect pregnancy and its prognosis. The use of assisted reproductive technologies (ART) can increase the probability of fertility in RDs. The aim of this study was to compare ART outcomes in women with versus without RDs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study was carried out between August 2023 and August 2024. Using medical records and documents, the ART outcomes of women with and without RDs were included. The descriptive statistics were provided as mean ± SD, number, and percentage. The distribution status of demographic and clinical variables was done through Mann–Whitney and Chi-squared or Fisher's exact test (for qualitative variables) and the confounder variables were adjusted. Data analysis was performed at a significance level of 5% using SPSS 25 software.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 194 women with 334 cycles of ART were included; 62 participants were with RDs while 132 were without RDs. This study demonstrated that women with RDs are at a significantly higher risk of miscarriage (OR = 5.27, CI 1.28 to 21.75, <i>p</i> = 0.021) and inadequate gestational weight gain during pregnancy (OR = 2.25, CI 1.06 to 4.75, <i>p</i> = 0.034) compared to those without RDs. Additionally, fetal/neonatal complications did not show significant differences between the two groups. However, studies with larger sample sizes may yield different results regarding fetal/neonatal outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These results emphasize the importance of personalized and multidisciplinary care for women with RDs, particularly during pregnancy, to manage risks and improve maternal and fetoneonatal outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144657598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of MRI T1 and T2 Grayscale Values and Sieper/Rudwaleit Score With Disease Activity and Progression in Ankylosing Spondylitis","authors":"Wantai Dang,&nbsp;Xinru Zheng,&nbsp;Luis E. Muñoz,&nbsp;Marco Muñoz-Becerra,&nbsp;Dan Xu,&nbsp;Martin Herrmann","doi":"10.1111/1756-185x.70373","DOIUrl":"https://doi.org/10.1111/1756-185x.70373","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to investigate the relationship between MRI T1 and T2 grayscale values and Sieper/Rudwaleit score with disease activity and inflammation levels in patients with ankylosing spondylitis (AS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Totally, 174 AS patients and 41 healthy controls were enrolled and received MRI and computed tomography (CT) of sacroiliac joints (SIJ).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sieper/Rudwaleit score positively related to CT grade (<i>p</i> = 0.038). MRI T1 values correlated negatively and positively to MRI T2 values (<i>p</i> = 0.001) and CT grade (<i>p</i> = 0.016), respectively. According to multiple linear regression analysis, Sieper/Rudwaleit score showed an independent positive correlation with bone marrow fat deposition and Bath ankylosing spondylitis disease activity index (BASDAI) (both <i>p</i> &lt; 0.001). MRI T1 values exhibited an independent positive correlation with male sex, duration of AS, and BASDAI; while they inversely related to C-reactive protein (CRP), platelets, albumin, and creatinine (all <i>p</i> &lt; 0.05). MRI T2 values exhibited an independent positive correlation with CRP and neutrophils, and a negative correlation to age, male sex, and creatinine (all <i>p</i> &lt; 0.05). CT grade disclosed an independent positive relationship with human leukocyte antigen B27 positivity, duration of AS, ankylosing spondylitis disease activity score, CRP, platelets, and alkaline phosphatase (all <i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MRI T1 and T2 values combined with the Sieper/Rudwaleit score may serve as potential biomarkers for evaluating inflammatory activity and disease progression in AS. CT serves as an adjunct to MRI to monitor the activity of AS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144657649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}